Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio su tiragolumab in combinazione con atezolizumab rispetto al placebo in combinazione con atezolizumab in pazienti con carcinoma polmonare non a piccole cellule selezionato per PD-L1 non resecabile o metastatico localmente avanzato precedentemente non trattato (SKYSCRAPER-01)

6 novembre 2026 aggiornato da: Hoffmann-La Roche

Uno studio di fase III, randomizzato, in doppio cieco, controllato con placebo su tiragolumab, un anticorpo anti-tigit, in combinazione con atezolizumab rispetto al placebo in combinazione con atezolizumab in pazienti con PD-L1 non selezionato localmente avanzato non resecabile o metastatico precedentemente non trattato -Cancro del polmone a piccole cellule

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participants with previously untreated locally advanced, unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Eligible participants will be randomized in a 1:1 ratio to receive either tiragolumab plus atezolizumab or placebo plus atezolizumab.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

620

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Queensland
      • Woolloongabba, Queensland, Australia, 4102
        • Princess Alexandra Hospital
    • Victoria
      • Heidelberg, Victoria, Australia, 3084
        • Austin Hospital Olivia Newton John Cancer Centre
      • Melbourne, Victoria, Australia, 3000
        • Peter Maccallum Cancer Centre
      • Linz, Austria, 4020
        • Ordensklinikum Linz Elisabethinen
      • Vienna, Austria, 1140
        • Klinik Penzing
      • Vienna, Austria, 1210
        • Krankenhaus Nord - Klinik Floridsdorf
    • Rio Grande do Sul
      • Ijuí, Rio Grande do Sul, Brasile, 98700-000
        • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda
    • São Paulo
      • Barretos, São Paulo, Brasile, 14784-400
        • Hospital de Cancer de Barretos
      • Beijing, Cina, 100142
        • Beijing Cancer Hospital
      • Changchun, Cina, 130021
        • The First Hospital of Jilin University
      • Chengdu, Cina, 610041
        • West China Hospital, Sichuan University
      • Chongqing, Cina, 400030
        • Chongqing Cancer Hospital
      • Fuzhou, Cina, 350014
        • Fujian Cancer Hospital
      • Haikou, Cina, 570311
        • Hainan General Hospital
      • Hangzhou, Cina, 310016
        • Sir Run Run Shaw Hospital Zhejiang University
      • Harbin, Cina, 150081
        • Harbin Medical University Cancer Hospital
      • Jinan, Cina, 250013
        • Jinan Central Hospital
      • Meizhou, Cina, 514031
        • Meizhou People's Hospital
      • Nanchang, Cina, 330200
        • The 1st Affiliated Hospital of Nanchang Unversity
      • Nantong, Cina, 226361
        • Nantong Tumor Hospital
      • Shanghai, Cina, 200433
        • Shanghai Pulmonary Hospital
      • Shanghai, Cina, 200032
        • Zhongshan Hospital Fudan University
      • Shanghai, Cina, 200120
        • Fudan University Shanghai Cancer Center
      • Wuhan, Cina, 430022
        • Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
      • Xi'an, Cina, 710061
        • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
      • Zhejiang, Cina, 310022
        • Zhejiang Cancer Hospital
      • Cheongju-si, Corea del Sud, 28644
        • Chungbuk National University Hospital
      • Gyeonggi-do, Corea del Sud, 13620
        • Seoul National University Bundang Hospital
      • Gyeonggi-do, Corea del Sud, 16499
        • Ajou University Medical Center
      • Incheon, Corea del Sud, 21565
        • Gachon University Gil Medical Center
      • Jeollanam-do, Corea del Sud, 58128
        • Chonnam National University Hwasun Hospital
      • Seoul, Corea del Sud, 03080
        • Seoul National University Hospital
      • Seoul, Corea del Sud, 05505
        • Asan Medical Center
      • Seoul, Corea del Sud, 03722
        • Severance Hospital, Yonsei University Health System
      • Seoul, Corea del Sud, 08308
        • Korea University Guro Hospital
      • Seoul, Corea del Sud, 6351
        • Samsung Medical Center
      • Seoul, Corea del Sud, 03181
        • Kangbuk Samsung Medical Center
      • Suwon, Corea del Sud, 442-723
        • St. Vincent's Hospital
      • Frankfurt, Germania, 60488
        • Krankenhaus Nordwest
      • Großhansdorf, Germania, 22927
        • LungenClinic Großhansdorf GmbH
      • Halle, Germania, 06120
        • Krankenhaus Martha-Maria Halle-Doelau gGmbH
      • Immenhausen, Germania, 34376
        • Fachklinik für Lungenerkrankungen
      • Löwenstein, Germania, 74245
        • SLK Kliniken Heilbronn GmbH, Standort Fachklinik Löwenstein
      • Münster, Germania, 48153
        • Gemeinschaftspraxis für Hämatologie und Onkologie
      • Stuttgart, Germania, 70376
        • Klinik Schillerhöhe
      • Aichi, Giappone, 464-8681
        • Aichi Cancer Center
      • Chiba, Giappone, 277-8577
        • National Cancer Center Hospital East
      • Fukuoka, Giappone, 812-8582
        • Kyushu University Hospital
      • Miyagi, Giappone, 980-0873
        • Sendai Kousei Hospital
      • Niigata, Giappone, 951-8566
        • Niigata Cancer Center Hospital
      • Osaka, Giappone, 589-8511
        • Kindai University Hospital
      • Osaka, Giappone, 541-8567
        • Osaka International Cancer Institute
      • Saitama, Giappone, 362-0806
        • Saitama Cancer Center
      • Sakaishi, Giappone, 591-8555
        • NHO Kinki-Chuo Chest Medical Center
      • Shizuoka, Giappone, 411-8777
        • Shizuoka Cancer Center
      • Tokyo, Giappone, 104-0045
        • National Cancer Center Hospital
      • Tokyo, Giappone, 135-8550
        • The Cancer Institute Hospital of JFCR
      • Athens, Grecia, 185 47
        • Metropolitan Hospital
      • Athens, Grecia, 104 31
        • Sotiria Hospital
      • Larissa, Grecia, 411 10
        • University Hospital of Larissa
      • Thessaloniki, Grecia, 570 01
        • Diavalkaniko Hospital
    • Campania
      • Naples, Campania, Italia, 80131
        • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
    • Lazio
      • Rome, Lazio, Italia, 00151
        • Azienda Ospedaliera San Camillo Forlanini
      • Rome, Lazio, Italia, 00168
        • Policlinico Universitario "Agostino Gemelli"
    • Lombardy
      • Milan, Lombardy, Italia, 20141
        • Irccs Istituto Europeo di Oncologia (IEO)
      • Monza, Lombardy, Italia, 20900
        • Asst Di Monza
      • Rozzano, Lombardy, Italia, 20089
        • Istituto Clinico Humanitas
    • Piedmont
      • Orbassano, Piedmont, Italia, 10043
        • Azienda Sanitaria Ospedaliera S Luigi Gonzaga
    • Umbria
      • Perugia, Umbria, Italia, 06156
        • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
    • Veneto
      • Padova, Veneto, Italia, 35128
        • IOV - Istituto Oncologico Veneto - IRCCS
    • Mexico CITY (federal District)
      • México, Mexico CITY (federal District), Messico, 06100
        • Cryptex Investigacion Clinica SA de CV
    • Nuevo León
      • Monterrey, Nuevo León, Messico, 64710
        • AVIX Investigación Clínica S.C
    • Querétaro
      • Querétaro City, Querétaro, Messico, 76000
        • Cuidados oncologicos
      • 's-Hertogenbosch, Olanda, 5223 GZ
        • Jeroen Bosch Ziekenhuis
      • Ede, Olanda, 6716 RP
        • Ziekenhuis Gelderse Vallei
      • Leeuwarden, Olanda, 8934 AD
        • Frisius MC Leeuwarden
      • The Hague, Olanda, 2545 AA
        • Hagaziekenhuis, locatie Leyweg
      • Arequipa, Perù, 5154
        • Instituto Regional de Enfermedades Neoplásicas del Sur
      • Lima, Perù, 15038
        • Instituto Nacional de Enfermedades Neoplasicas
      • Lima, Perù, Lima 41
        • Clinica Internacional, Sede San Borja
      • San Isidro, Perù, Lima 27
        • Clinica Ricardo Palma
      • Gda?sk, Polonia, 80-214
        • Uniwersyteckie Centrum Kliniczne
      • Olsztyn, Polonia, 10-357
        • Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
      • Poznan, Polonia, 60-569
        • Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
    • Moscow Oblast
      • Moscow, Moscow Oblast, Russia, 143422
        • MEDSI Clinical Hospital on Pyatnitsky Highway
      • Moscow, Moscow Oblast, Russia, 105229
        • Main Military Clinical Hospital named after N.N. Burdenko
    • Sankt-Peterburg
      • Saint Petersburg, Sankt-Peterburg, Russia, 194291
        • Leningrad Regional Clinical Hospital
      • Saint Petersburg, Sankt-Peterburg, Russia, 189646
        • Institute of Oncology
      • Saint Petersburg, Sankt-Peterburg, Russia, 197089
        • St. Petersburg Med Univ
      • Saint Petersburg, Sankt-Peterburg, Russia, 197758
        • St. Petersburg Clinical Scientific Center of special services medical assis (oncology)
      • Belgrade, Serbia, 11000
        • Clinical Center of Serbia
      • Belgrade, Serbia, 11080
        • University Hospital Medical Center Bezanijska kosa
      • Madrid, Spagna, 28041
        • Hospital 12 de Octubre
      • Madrid, Spagna, 28222
        • Hospital Universitario Puerta de Hierro - Majadahonda
      • Madrid, Spagna, 41013
        • Hospital Universitario Virgen del Rocío
      • Málaga, Spagna, 29010
        • Hospital Regional Universitario de Malaga
      • Zaragoza, Spagna, 50009
        • Hosp Clinico Univ Lozano Blesa
    • Barcelona
      • Badalona, Barcelona, Spagna, 08916
        • Hospital Universitario Germans Trias i Pujol
    • Colorado
      • Denver, Colorado, Stati Uniti, 80220
        • Rocky Mountain Cancer Center - Denver
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06520
        • Yale Cancer Center
    • Florida
      • St. Petersburg, Florida, Stati Uniti, 33705
        • SCRI Florida Cancer Specialists North
      • Tallahassee, Florida, Stati Uniti, 32308
        • SCRI Florida Cancer Specialists PAN
    • Minnesota
      • Saint Paul, Minnesota, Stati Uniti, 55102
        • US oncology research at Minnesota Oncology
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • SCRI Oncology Partners
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • Virginia Cancer Specialists (Fairfax) - USOR
      • Salem, Virginia, Stati Uniti, 24153
        • Onc & Hem Assoc SW Virginia
      • Bern, Svizzera, 3010
        • Inselspital Bern
      • Lausanne, Svizzera, 1011
        • CHUV
      • Sankt Gallen, Svizzera, 9000
        • HOCH Health Ostschweiz, Kantonsspital St. Gallen
      • Bangkok, Tailandia, 10330
        • Chulalongkorn Hospital
      • Bangkok, Tailandia, 10400
        • Ramathibodi Hospital
      • Bangkok, Tailandia, 10700
        • Faculty of Med. Siriraj Hosp.
      • Songkhla, Tailandia, 90110
        • Songklanagarind Hospital
      • Guishan Dist., Taiwan, 33305
        • Chang Gung Memorial Hospital - Linkou Branch
      • Kaohsiung City, Taiwan, 83301
        • Kaohsiung Chang Gung Memorial Hospital
      • Kaohsiung City, Taiwan, 807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • New Taipei City, Taiwan, 23561
        • Taipei Medical University ?Shuang Ho Hospital
      • Taichung, Taiwan, 407
        • Taichung Veterans General Hospital
      • Tainan, Taiwan, 704
        • National Cheng Kung Uni Hospital
      • Taipei, Taiwan, 112
        • Taipei Veterans General Hospital
      • Zhongzheng Dist., Taiwan, 10048
        • National Taiwan University Hospital
      • Adana, Turchia (Türkiye), 01120
        • Adana Baskent University Hospital
      • Ankara, Turchia (Türkiye), 06100
        • Hacettepe University Medical Faculty
      • Istanbul, Turchia (Türkiye), 34098
        • Istanbul University Cerrahpasa Faculty of Medicine
      • Izmir, Turchia (Türkiye), 35110
        • Izmir Dr. Suat Seren Gogus Hastaliklari ve Cerrahisi Egitim ve Arastirma Hastanesi
      • Kadiköy, Turchia (Türkiye), 34722
        • Goztepe Prof.Dr. Suleyman Yalcin City Hospital
      • Malatya, Turchia (Türkiye), 44280
        • Inonu University Medical Faculty of Medicine
      • Kryvyi Rih, Ucraina, 50048
        • ME Kryviy Rih Oncology Dispensary of Dnipropetrovs?k Regional Council
      • Uzhhorod, Ucraina, 88000
        • Uzhgorod Nat. University Central Municip Hosp
      • Budapest, Ungheria, 1121
        • Orszagos Koranyi TBC es Pulmonologiai Intezet
      • Mátraháza, Ungheria, 3233
        • Matrai Gyogyintezet
      • Szolnok, Ungheria, 5004
        • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  • Histologically or cytologically documented locally advanced or recurrent NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemoradiotherapy, or metastatic Stage IV non-squamous or squamous NSCLC
  • No prior systemic treatment for metastatic NSCLC
  • High tumor tissue PD-L1 expression
  • Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
  • Adequate hematologic and end-organ function
  • For participants enrolled in the extended China enrollment phase: current resident of mainland China or Taiwan and of Chinese ancestry.

Exclusion Criteria:

  • Known mutation in the EGFR gene or an ALK fusion oncogene
  • Symptomatic, untreated, or actively progressing central nervous system metastases
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis
  • Malignancies other than NSCLC within 5 years, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Positive test result for human immunodeficiency virus (HIV)
  • Active hepatitis B or hepatitis C
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to initiation of study treatment.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Tiragolumab + Atezolizumab

Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

Altri nomi:
  • Tecentriq

Tiragolumab 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Altri nomi:
  • MTIG7192A
Comparatore placebo: Placebo + Atezolizumab

Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.

Atezolizumab 1200 milligrams (mg) administered by intravenous (IV) infusion Q3W on Day 1 of each 21-day cycle.

Altri nomi:
  • Tecentriq

Matching Placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Global Cohort: Investigator-assessed Progression-free Survival (PFS) After Randomization According to RECIST v1.1 in the Primary Analysis Set (PAS)
Lasso di tempo: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)

PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm) or unequivocal progression of existing non-target lesions. Kaplan-Meier (K-M) method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS After Randomization According to RECIST v1.1 in the PAS
Lasso di tempo: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)

PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the PAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: Overall Survival (OS) in the PAS
Lasso di tempo: From randomization to death from any cause (up to approximately 54.7 months)

OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the PAS
Lasso di tempo: From randomization to death from any cause (up to approximately 49.1 months)

OS was defined as the time from randomization to death from any cause in the PAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Number of Participants With Adverse Events (AEs)
Lasso di tempo: Up to 65.1 months

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to 65.1 months
China Cohort: Number of Participants With AEs
Lasso di tempo: Up to 49.3 months

An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to 49.3 months
Global Cohort: Number of Participants With Cytokine Release Syndrome (CRS), With Severity Determined by American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
Lasso di tempo: Up to 65.1 months

CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

Up to 65.1 months
China Cohort: Number of Participants With CRS, With Severity Determined by ASTCT Consensus Grading Scale
Lasso di tempo: Up to 49.3 months

CRS was defined as supraphysiologic response following administration of immune therapy that results in activation/engagement of endogenous or infused T-cells and/or other immune effector cells. Symptoms include fever, hypotension, hypoxia, & end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades- Grade 1: fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension & hypoxia; Grade 2: fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring oxygen by positive-pressure; Grade 5: death due to CRS.

Up to 49.3 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Global Cohort: Investigator-assessed PFS According to RECIST v1.1 in the Secondary Analysis Set (SAS)
Lasso di tempo: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24.2 months)
China Cohort: Investigator-assessed PFS According to RECIST v1.1 in the SAS
Lasso di tempo: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first in the SAS. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the median PFS.

From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 48.4 months)
Global Cohort: OS in the SAS
Lasso di tempo: From randomization to death from any cause (up to approximately 54.7 months)

OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 54.7 months)
China Cohort: OS in the SAS
Lasso di tempo: From randomization to death from any cause (up to approximately 49.1 months)

OS was defined as the time from randomization to death from any cause in the SAS. K-M method was used to estimate the median OS.

From randomization to death from any cause (up to approximately 49.1 months)
Global Cohort: Investigator-assessed Confirmed Objective Response Rate (ORR) According to RECIST v1.1 in the PAS
Lasso di tempo: Up to approximately 54.6 months

Confirmed ORR was defined as the percentage of participants with a confirmed objective response (OR), characterized by either a complete response (CR) or a partial response (PR), on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Up to approximately 54.6 months
China Cohort: Investigator-assessed Confirmed ORR According to RECIST v1.1 in the PAS
Lasso di tempo: Up to 49.3 months

Confirmed ORR was defined as the percentage of participants with a confirmed OR, characterized by either a CR or a PR, on 2 consecutive occasions ≥ 4 weeks apart, as determined by the investigator per RECIST v1.1 in the PAS. CR was defined as the disappearance of all target and non-target lesions & normalization of tumor marker level. Additionally, any pathological lymph nodes (whether target or non-target) must have a reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.

Up to 49.3 months
Global Cohort: Investigator-assessed Duration of Response (DOR) According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
Lasso di tempo: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)

DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 54.6 months)
China Cohort: Investigator-assessed DOR According to RECIST v1.1 for Participants With Confirmed ORR in the PAS
Lasso di tempo: From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)

DOR for participants with confirmed ORR was defined as time from first occurrence of confirmed OR (CR or PR) to PD, as determined by the investigator per RECIST v1.1, or death from any cause, whichever occurred first in PAS. CR was defined as disappearance of all target & non-target lesions & normalization of tumor marker level. Additionally, any lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in SOD of all target lesions, taking as reference baseline SOD, in absence of CR. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference smallest SOD at prior timepoints (including baseline). Additionally, SOD must also demonstrate absolute increase of ≥5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate median DOR.

From first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to 49.3 months)
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
Lasso di tempo: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the PAS
Lasso di tempo: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the PAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
Global Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
Lasso di tempo: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
China Cohort: Investigator-assessed PFS Rate at 6 Months and 12 Months in the SAS
Lasso di tempo: At Months 6 and 12

PFS rate at 6 months and 12 months was defined as the percentage of participants who did not experience PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization in the SAS. PFS after randomization was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD at prior timepoints (including baseline). Additionally, the SOD must also demonstrate an absolute increase of ≥ 5 mm or unequivocal progression of existing non-target lesions. K-M method was used to estimate the PFS rate. Percentages have been rounded off.

At Months 6 and 12
Global Cohort: OS Rate at 12 Months and 24 Months in the PAS
Lasso di tempo: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
China Cohort: OS Rate at 12 Months and 24 Months in the PAS
Lasso di tempo: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the PAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
Global Cohort: OS Rate at 12 Months and 24 Months in the SAS
Lasso di tempo: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
China Cohort: OS Rate at 12 Months and 24 Months in the SAS
Lasso di tempo: At Months 12 and 24

OS rate at 12 months and 24 months was defined as the percentage of participants who did not experience death from any cause at 12 months and 24 months after randomization in the SAS. OS was defined as the time from randomization to death from any cause. K-M method was used to estimate the OS rate. Percentages have been rounded off.

At Months 12 and 24
Global Cohort: Time to Confirmed Deterioration (TTCD) in Participant-reported Physical Functioning (PF), as Measured by European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) in the PAS
Lasso di tempo: Up to approximately 54.6 months

TTCD was defined as the time from randomization to first confirmed clinically meaningful deterioration (CCMD). EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), global health status (GHS)/quality-of-life (QoL), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 54.6 months
China Cohort: TTCD in Participant-reported PF, as Measured by EORTC QLQ-C30 in the PAS
Lasso di tempo: Up to approximately 49.3 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). Functioning was scored on 4-point scale: 1=Not at all to 4=Very much. Scores were linearly transformed to range of 0-100. High score for PF scale=high/healthy level of functioning. CCMD=Clinically meaningful decrease (≥10 points) from baseline in PF score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 49.3 months
Global Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
Lasso di tempo: Up to approximately 54.6 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better health-related quality-of-life (HRQoL). CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 54.6 months
China Cohort: TTCD in Participant-reported GHS/QoL, as Measured by EORTC QLQ-C30 in the PAS
Lasso di tempo: Up to approximately 49.3 months

TTCD was defined as the time from randomization to first CCMD. EORTC QLQ-C30 is a cancer-specific instrument with 30 questions to evaluate 5 aspects of functioning (physical, emotional, role, cognitive, social), 3 symptom scales (fatigue, nausea, vomiting, pain), GHS/QoL, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea & financial difficulties). GHS/QoL questions were scored on 7-point scale: 1=Very poor to 7=Excellent. Scores were linearly transformed to range of 0-100. High score for GHS/QoL scale=better HRQoL. CCMD=Clinically meaningful decrease (≥10 points) from baseline in GHS/QoL score held for at least 2 consecutive assessments or an initial clinically meaningful decrease above baseline followed by death from any cause within 6 weeks. K-M method was used to estimate median TTCD.

Up to approximately 49.3 months
Global Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Lasso di tempo: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-end of infusion (EOI) on Day 1 of Cycle 1; Treatment discontinuation (TD) visit (up to approximately 54.6 months) (1 Cycle=21 days)
China Cohort: Serum Concentration of Tiragolumab at Specified Timepoints
Lasso di tempo: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, and 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Global Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Lasso di tempo: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 54.6 months) (1 Cycle=21 days)
China Cohort: Serum Concentration of Atezolizumab at Specified Timepoints
Lasso di tempo: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16; 30 minutes post-EOI on Day 1 of Cycle 1; TD visit (up to approximately 49.3 months) (1 Cycle=21 days)
Global Cohort: Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
Lasso di tempo: Up to approximately 54.6 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 54.6 months
China Cohort: Number of Participants With ADAs to Tiragolumab
Lasso di tempo: Up to approximately 49.3 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 49.3 months
Global Cohort: Number of Participants With ADAs to Atezolizumab
Lasso di tempo: Up to approximately 54.6 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 54.6 months
China Cohort: Number of Participants With ADAs to Atezolizumab
Lasso di tempo: Up to approximately 49.3 months

Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin, such as at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). Participants with a positive post-baseline sample have been reported here.

Up to approximately 49.3 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Clinical Trial, Hoffmann-La Roche

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 marzo 2020

Completamento primario (Effettivo)

30 dicembre 2025

Completamento dello studio (Effettivo)

30 dicembre 2025

Date di iscrizione allo studio

Primo inviato

2 marzo 2020

Primo inviato che soddisfa i criteri di controllo qualità

2 marzo 2020

Primo Inserito (Effettivo)

4 marzo 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • GO41717
  • 2019-002925-31 (Numero EudraCT)
  • 2019 (Sovvenzione/contratto NIH degli Stati Uniti)
  • 2022-502482-17-00 (Ctis)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi